MSLN and cancer: Chimeric monoclonal antibodies (amatuximab), antibody–drug conjugates (anetumab ravtansine, BMS-986148, and BAY2287411), immunotoxins (SS1P and LMB-100), a cancer vaccine (Listeria monocytogenes vaccine expressing MSLN), and CAR T cell immunotherapy are among the immunotherapy approaches that target MSLN in MPM.